PHILADELPHIA, PA -- (Marketwire) -- 05/20/09 -- Eurand N.V. (NASDAQ: EURX), a specialty
pharmaceutical company that develops enhanced pharmaceutical and
biopharmaceutical products based on its proprietary pharmaceutical
technologies, announced today that GearĂ³id Faherty, Chairman and Chief
Executive Officer, is scheduled to present at the following conference:
Event: UBS Global Specialty Pharmaceuticals Conference
Date: Tuesday, June 2, 2009
Time: 11:00 a.m. BST (6:00 a.m. ET)
Location: The Waldorf Hilton Hotel
London, U.K.
An audio webcast of the Company's presentation will be available by
accessing the investor relations section of Eurand's web site at
www.eurand.com and will be available via replay until July 2, 2009.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures
and commercializes enhanced pharmaceutical and biopharmaceutical products
based on its proprietary pharmaceutical technologies. Eurand has had five
products approved by the FDA since 2001 and has a pipeline of product
candidates in development for itself and its collaboration partners. The
Company's technology platforms include bioavailability enhancement of
poorly soluble drugs, custom release profiles, taste-masking orally
disintegrating tablet (ODT) formulations, and drug conjugation.
Eurand is a global company with facilities in the U.S. and Europe. For
more information, visit www.eurand.com.
Contacts:
Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1 267-759-9335
Email Contact
Nick Laudico/Sara Pellegrino
The Ruth Group
+1 646-536-7030/7002
Email Contact
Email Contact